Marker Therapeutics (MRKR): which funds own it

Who owns Marker Therapeutics?

Holders reporting more than 5% of the shares to the SEC (Schedules 13D/13G): Blue Owl Capital Holdings, 10.0% (13G/A filed May 15, 2025), New Enterprise Associates 16, 9.9% (13D/A filed Nov 17, 2025) and Alyeska Investment Group, 9.9% (13G/A filed Nov 14, 2025). NEA Partners 16, L.P. is listed on Form 4 filings as an owner of more than 10%. As of Jun 30, 2026, the largest holders reported on Form 13F were NEA Management (9.8% of the shares), Blue Owl Capital Holdings (3.3%) and Vanguard Capital Management (2.6%).

Sources:13G/A by Blue Owl Capital Holdings (May 15, 2025) ↗13D/A by New Enterprise Associates 16 (Nov 17, 2025) ↗13G/A by Alyeska Investment Group (Nov 14, 2025) ↗All of the company's proxy statements on EDGAR ↗

13F percentages divide the shares each institution reports by the shares outstanding on the cover of the company's latest report before the quarter end (May 8, 2026). Entities of the same group file separately and are not added up. We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.

• NEA Management1.6 MPrivate equity or venture capital · 9.75% of the company0
• Blue Owl Capital Holdings554 KPrivate equity or venture capital · 3.32% of the company0
• Vanguard Capital Management426 KIndex manager · 2.56% of the company+37 K
• Aisling Capital Management325 KPrivate equity or venture capital · 1.95% of the company0
• Renaissance Technologies249 KQuant or multi-manager · 1.50% of the company+74 K
• Geode Capital Management140 KIndex manager · 0.84% of the company−21 K
• Osaic Holdings113 KWealth adviser · 0.68% of the company+20 K
• Vanguard Fiduciary Trust87 KIndex manager · 0.52% of the company0
• LPL Financial83 KWealth adviser · 0.50% of the company+100
• Concurrent Investment Advisors68 KType not verified · 0.41% of the company+68 K

The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.

Held by institutions (13F)

Institutions (13F): 23.8% of the shares · top 10: 22.0% · in index firms: 17.9% of the institutional total

Shares reported by the 35 13F filers as of Jun 30, 2026 (not counting 1 position with implausible figures), divided by the shares outstanding on the cover of the company's latest report (May 8, 2026). It is not all institutional ownership: only managers above $100M file a 13F, and it excludes short positions. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. We only publish it where the figure is credible: not for ADRs, companies with more than one share class or stale shares-outstanding data.

Shares outstanding: buybacks and dilution

From the statements the company filed with the SEC (10-K). The change compares average diluted shares of each fiscal year, on today's basis: negative = it bought back more than it issued; positive = dilution. “No data” = the company does not report that item under a tag we can read; it does not mean zero.

Earnings quality and debt

From the figures the company filed with the SEC. Cash flow over net income near or above 1 means earnings are collected in cash; far below, that part is accounting. Coverage says how many times operating income pays the latest fiscal year's interest. Maturities come from the debt note of the latest annual report, counted from its closing date. “No data” never means zero.

Above 5% over time (13D/13G)

Each holder with its filings in order. History since December 2024.

Flagged material events (8-K)

• Nov 5, 2025Routinefiling ↗

  Change in directors or officers (Item 5.02)

  «Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors»

Alert items the company itself flagged in its 8-K filings with the SEC, most serious first. It is the form's label, with no interpretation from us: Item 5.02 covers routine appointments as well as a chief executive's departure; open the filing. The quoted headline is the original press release's.